Table 3.
Clinical, Histopathologic, and FISH Data of the 760 RET-FISH-Positive and -Negative NSCLC Samples
| N = 760 | RET-FISH-Positive Samples (≥15%) n = 32 | RET-FISH-Negative Samples (<15%) n = 728 |
|---|---|---|
| Patient gender, n (%) | ||
| M | 18 (56) | 493 (68) |
| F | 14 (44) | 235 (32) |
| Patient age, mean, median (range) | ||
| M | 70, 71 (51–86) | 68, 69 (21–94) |
| F | 67, 65 (48–82) | 66, 66 (29–93) |
| Histology, n (%) | ||
| Adenocarcinoma | 24 (75) | 583 (80.1) |
| Squamous cell carcinoma | 0 | 7 (1.0) |
| Sarcomatoid carcinoma | 0 | 3 (0.4) |
| (large cell) neuroendocrine carcinoma | 1 (3.1) | 6 (0.8) |
| Other type of carcinoma | 7 (21.9) | 129 (17.7) |
| Type of sample, n (%) | ||
| Lung resection | 7 (21.9) | 123 (16.9) |
| Resection of metastatic site | 4 (12.5) | 70 (9.6) |
| Lung biopsy | 13 (40.6) | 344 (47.3) |
| Biopsy of metastatic site | 5 (15.6) | 132 (18.1) |
| Cytologic sample | 3 (9.4) | 59 (8.1) |
| % of tumor cells in the analyzed sample, n (%) | ||
| <20% | 5 (15.6) | 86 (11.8) |
| 20%–50% | 20 (62.5) | 434 (59.6) |
| >50% | 7 (21.9) | 203 (27.9) |
| Not specified | 0 | 5 (0.7) |
| Number of nuclei analyzed by FISH, mean (range) | 105 (84–128) | 105 (60–311) |
| % of RET-FISH positive nuclei mean, median (range) | 55.3%, 57.7% (17.7%–94%) | 4.4%, 3.9% (0–14.3%) |
F, female; FISH, fluorescence in situ hybridization; M, male.